Bright Minds Biosciences will present scientific posters about various programs in development, including BMB-101, BMB-201 and BMB-202 Bright Minds Biosciences will participate in BIO Europe partnering event and Chicago Biocapital Summit to present its innovation in neuroscience NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other ...

Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drugresistant epilepsy disorders with high unmet needs BMB-101 is a novel highly selective 5-HT2C agonist. Its G-protein biased agonism provides an improved mechanism of action for chronic dosing Financial runway extending into 2026 enabling key data readout Conference call & KOL Event – will be held as a webcast on September 25th at 10:00 ET NEW YORK, Sept. 12, 2024 /PRNewswire/ - Bright Minds Biosciences Inc. (NASD ...

Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the nine months ended June 30, 2024 and 2023 (Expressed in Canadian Dollars) 1 | P a g e June 30, September 30, | --- | --- | --- | --- | |---------------------------------|-------|------------------|----------------| | As at | Notes | 2024 (unaudited) | 2023 (audited) | | | | $ | $ | | ASSETS | | | | | Current Assets | | | | | Cash and cash equivalents | 8 | 6,190,244 | 6,747,986 | | Sales tax receivable | | 17,236 | 36,9 ...

To report suspected adverse reactions, contact Harmony Biosciences at 1-800-833-7460 or the FDA at 1-800- FDA-1088 or www.fda.gov/medwatch. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our product WAKIX. These statements are neither promises nor guar ...

"Following the FDA's decision to grant priority review, we are very pleased with the Agency's timely review and approval of WAKIX for pediatric narcolepsy patients with excessive daytime sleepiness," said Jeffrey M. Dayno, M.D., President and Chief Executive Officer of Harmony Biosciences. "EDS is the primary symptom experienced by all patients with narcolepsy and this approval for WAKIX, as the first-and-only FDA-approved non-scheduled treatment option for narcolepsy, makes this important treatment option ...

Title: TGFB2 therapeutic for the treatment of CRC, GBM, and PDAC Abstract: OT-101, an antisense against TGFB2, is being tested in phase 3 clinical trials for pancreatic cancer and glioblastoma. It was previously reported to have robust clinical activity in those indications as well as in melanoma. Here, we explore the potential application of OT-101 in colorectal cancer (CRC) through the analysis of CRC patients treated with OT-101 during its clinical development, as well as through bioinformatic. Intraveno ...

Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the six months ended March 31, 2024 and 2023 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars) | | | March 31, | September 30, | | --- | --- | --- | --- | | | | 2024 | 2023 | | As at | Notes | (unaudited) | (audited) | | | | $ | $ | | ASSETS | | | | | Current Assets | | | | | Cash and cash equivalents | 8 | 5,932,436 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of Each Class Trading Symbol(s) Name of each exchange on which registered Common Shares DRUG The Nasdaq Stock Market LLC FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURIT ...

Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three and nine months ended June 30, 2022 and 2021 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars - Unaudited) | --- | --- | --- | --- | |------------------------------------------------------------|-------|--------------------|----------------------| | As at | Notes | June 30, 2022 | September 30, 2021 | | | | ...

Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three and six months ended March 31, 2022 and 2021 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars - Unaudited) | --- | --- | --- | --- | |----------------------------------------------------|-------|--------------------|----------------------| | As at | Notes | March 31, 2022 | September 30, 2021 | | | | $ | $ ...